Juergen Wolf. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients with MET exon-14 skipping mutated advanced non-small cell lung cancer. Abstract #LBA52. 2018 European Society of Medical Oncology (ESMO), October 19-23, 2018, Munich, Germany.
Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017; 16(4):555-565.
Tong JH, Yeung SF, Chan AWH, et al.. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res. 2016; 22(12):3048-3056.